Clinical Trial Update: Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma [Phase 2]

View source ↗

Summary

Phase II trial of sunitinib in patients with recurrent or inoperable meningioma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Cancer
• Hemangioblastoma
• Intracranial Hemangiopericytoma
• Meningioma
• Neurofibromatosis

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: CNS Cancer, Meningioma | Phase 2 | Status: COMPLETED | Results posted: 2016-01-25